An official website of the United States government
Publication Information
Affiliation
Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Authors
Acute Liver Study Group, Attar N, Battenhouse H, Blei A, Brown R, Chung RT, Crippin J, Davern T, Dillon C, Durkalski V, Fix O, Fontana R, Ganger D, Goddard T, Han SH, Harrison E, Hassanein T, Hay J, Hynan LS, Lalani E, Larson AM, Lee WM, Liou I, McCashland T, McGuire B, Metushi IG, Munoz S, Murray N, Pezzia C, Reddy R, Reuben A, Rossaro L, Samuel G, Sanders C, Satyanarayana R, Shaikh A, Smith A, Stravitz R, Uetrecht J, Zaman A, Zhao W
Studies
Citation
Metushi IG, Sanders C, Acute Liver Study Group, Lee WM, Uetrecht J. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology 2014 Mar;59(3):1084-93. Epub 2014 Jan 27.Abstract
Isoniazid (INH)-induced hepatotoxicity remains one of the most common causes of drug-induced idiosyncratic liver injury and liver failure. This form of liver injury is not believed to be immune-mediated because it is not usually associated with fever or rash, does not recur more rapidly on rechallenge, and previous studies have failed to identify anti-INH antibodies (Abs). In this study, we found Abs present in sera of 15 of 19 cases of INH-induced liver failure. Anti-INH Abs were present in 8 sera; 11 had anti-cytochrome P450 (CYP)2E1 Abs, 14 had Abs against CYP2E1 modified by INH, 14 had anti-CYP3A4 antibodies, and 10 had anti-CYP2C9 Abs. INH was found to form covalent adducts with CYP2E1, CYP3A4, and CYP2C9. None of these Abs were detected in sera from INH-treated controls without significant liver injury. The presence of a range of antidrug and autoAbs has been observed in other drug-induced liver injury that is presumed to be immune mediated.